Citi analyst Yigal Nochomovitz believes the approval of Neurocrine Biosciences' (NBIX) Ingrezza following a canceled advisory panel has a positive read-across to the ongoing FDA review for Portola Pharmaceuticals' (PTLA) betrixaban. The FDA had originally informed Portola to anticipate an advisory panel back in late December 2016, but in early February 2017 we learned the FDA was no longer requesting a panel, Nochomovitz tells investors in a research note. Ingrezza makes it four drugs out of four that got approved when a panel was canceled and there were no significant review issues identified by the FDA, the analyst adds, citing his analysis. The analyst notes he confirmed with Portola that no material issues were raised at the mid-cycle communication with the FDA on betrixaban. He keeps a Buy rating on Portola with a $51 price target.